Bank of America nearly doubled its peak sales estimate for J&J's Icotyde pill and lifted the JNJ price target ahead of Q3 ...
Johnson & Johnson (NYSE: JNJ) today announced new two-year data from the Phase 3 ICONIC-TOTALa study demonstrating the ...
An investigational therapy, SSGJ-608, was associated with substantial skin clearance through 52 weeks among patients with plaque psoriasis.
Bank of America nearly doubled its peak sales estimate for one Johnson & Johnson drug ahead of the company’s third-quarter ...
The European Commission has approved ICOTYDE® for eligible psoriasis patients aged 12 and over. The once-daily oral peptide ...
Johnson & Johnson's ICOTYDE oral psoriasis pill maintains 70% clear/almost-clear skin rates at 2 years, with no new safety ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Plaque psoriasis affects ~2% of the population and is linked to cardiovascular disease (CVD), psoriatic arthritis (PsA), metabolic syndrome, NAFLD, and depression/anxiety—burdens that rise with skin s ...
The real opportunity is pill-form peptides that could hit big pharma’s most profitable franchises.
(AMGN) has completed a Phase 3 study called “A Phase 3, Multicenter, Open-label, Single-arm Study to Assess the Efficacy and Safety of Apremilast (AMG 407) in Japanese Pediatric Subjects From 6 ...
The once-daily IL-23-targeted pill showed high rates of skin clearance and itch improvement in adults with moderate-to-severe plaque psoriasis.
Simone Biles opens up about her experience managing the symptoms of these conditions and encourages long-term control of skin healthBiles’ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results